Merck & Co.
AWARDS
NEWS
Merck had the unusual case of having its checkpoint inhibitor Keytruda (pembrolizumab) approved simultaneously in three countries for advanced endometrial carcinoma.
50 million people worldwide live with symptomatic Alzheimer’s, which has no cure. In honor of September 21st being World Alzheimer’s Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
The U.S. Food and Drug Administration approved Keytruda in combination with Eisai’s Lenvima for the treatment of patients with advanced endometrial carcinoma.
September has been a relatively slow month for the U.S. Food and Drug Administration. However, there are two PDFUA dates remaining, although one of those took an unexpected turn that will delay it until later in the year.
Eisai Co., Ltd. announced that it provides tanks to supply clean water for the neglected tropical diseases (NTDs) measuresto the endemic regions in Kenya in collaboration with Merck.
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) has been approved for 21 indications, but you’d better keep up, because it seems the drug is approved for some new indication or combination just about every week.
JOBS
IN THE PRESS